- Oppenheimer Biotech by the Lake 2020 Investor
Summit at 11:25 a.m. ET on
May 28th –
- Jefferies Global Virtual Healthcare Conference at 4:30 p.m. ET on June
3rd -
VANCOUVER, May 27, 2020 /CNW/ - Sierra Oncology, Inc.
(SRRA), a late-stage drug development company focused on the
registration and commercialization of momelotinib, a JAK1, JAK2
& ACVR1 inhibitor with a potentially differentiated therapeutic
profile for the treatment of myelofibrosis, today announced that
Dr. Barbara Klencke, Chief
Development Officer, will present the company at the upcoming
Jefferies Global Virtual Healthcare Conference and at the
Oppenheimer Biotech by the Lake 2020 Investor Summit.
Presentation details:
Conference:
|
Oppenheimer Biotech
by the Lake 2020 Investor Summit
|
Date:
|
Thursday, May 28,
2020
|
Time:
|
11:25 am.
ET
|
|
|
Conference:
|
Jefferies Global
Virtual Healthcare Conference
|
Date:
|
Wednesday, June 3,
2020
|
Time:
|
4:30 p.m.
ET
|
Webcast:
|
Listen to a live
audio webcast or archive of this presentation at
www.sierraoncology.com.
|
About Sierra Oncology
Sierra Oncology is a late stage
drug development company focused on achieving the successful
registration and commercialization of momelotinib, a potent,
selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor
with a targeted mechanism of action that enables it to address all
three key drivers of myelofibrosis. Momelotinib's differentiated
therapeutic profile encompasses robust constitutional symptom
improvements, a range of meaningful anemia benefits, including
eliminating or reducing the need for frequent blood transfusions,
and comparable spleen control to ruxolitinib. More than 1,200
subjects have received momelotinib since clinical studies began in
2009, including more than 820 patients treated for
myelofibrosis.
Sierra has launched MOMENTUM, a randomized double-blind Phase 3
clinical trial designed to enroll 180 myelofibrosis patients who
are symptomatic and anemic, and who have been treated previously
with a JAK inhibitor. The U.S. Food and Drug Administration has
granted Fast Track designation to momelotinib. Momelotinib is
protected by patents anticipated to provide potential exclusivity
to 2040 in the United States and
Europe (inclusive of potential
Patent Term Extension or Supplementary Protection Certificate).
For more information, please
visit www.sierraoncology.com.
Cautionary Note on Forward-Looking Statements
This
press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements regarding Sierra Oncology's expectations from current
data, anticipated clinical development activities, and potential
benefits of momelotinib. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These statements are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to
differ materially from those described in the forward-looking
statements. Such forward-looking statements are subject to risks
and uncertainties, including, among others, the risk that Sierra
Oncology's cash resources may be insufficient to fund its current
operating plans and it may be unable to raise additional capital
when needed, the risk that disruptions and impacts of COVID-19 will
be significant and lengthy, Sierra Oncology may be unable to
successfully develop and commercialize momelotinib,
momelotinib may not demonstrate safety and efficacy or
otherwise produce positive results, Sierra Oncology may experience
delays in the clinical development of momelotinib, Sierra Oncology
may be unable to acquire additional assets to build a pipeline of
additional product candidates, Sierra Oncology's third-party
manufacturers may cause its supply of materials to become limited
or interrupted or fail to be of satisfactory quantity or quality,
Sierra Oncology may be unable to obtain and enforce intellectual
property protection for its technologies and momelotinib and the
other factors described under the heading "Risk Factors" set forth
in Sierra Oncology's filings with the Securities and Exchange
Commission from time to time. Sierra Oncology undertakes no
obligation to update the forward-looking statements contained
herein or to reflect events or circumstances occurring after the
date hereof, other than as may be required by applicable law.
View original
content:http://www.prnewswire.com/news-releases/sierra-oncology-announces-presentations-at-upcoming-investor-conferences-301065651.html
SOURCE Sierra Oncology